Element Biosciences

Phase A — Understand the business

Lens 1 · Company Overview

Element Biosciences is a San Diego DNA-sequencing instruments company, founded 2017 by three ex-Illumina scientists — Molly He (CEO), Michael Previte (CTO), and Matthew Kellinger (head of biochemistry). The business model is the classic "razor-and-blades" tools model: sell a benchtop sequencing instrument (the razor, one-time capital) and then earn recurring, higher-margin revenue on consumables / sequencing kits (the blades) run on that box. This is the same model Illumina built a ~$4B/yr franchise on; Element is attacking the low-to-mid-throughput benchtop tier of it.

Products (the instrument ladder):

• AVITI — the flagship benchtop short-read sequencer, launched 2022; instrument list price ~$289,000. Delivers a ~$200 whole genome at ~$5–7/Gb running cost. Its wedge vs. Illumina is capital cost: $289K vs. Illumina's NovaSeq X at ~$985K–$1M.
• AVITI24 — a "5D multiomics" benchtop system with Teton CytoProfiling: direct single-cell/spatial imaging of DNA, RNA, protein, phospho-protein and cell morphology in up to ~2M cells per 24-hour run. Available; expanding via a Certified Service Provider program (first partners OMAPiX + Cornell Epigenomics, Dec 2025).
• VITARI — announced Feb 2026 at Element's "Beyond" event: the first high-throughput benchtop system to hit a $100 genome; list $689,000; up to 10B reads/run (2×150); ships H2 2026, pre-orders open. This is the direct answer to Ultima's cost attack.
• AVITI Dx — the clinical version: a Class A IVDR platform for clinical labs, built on the same chemistry, targeting a CE-IVD filing in the EU and availability late 2026 in select countries. ISO 13485 certification achieved (2026) — the prerequisite QMS milestone for IVD filings.

Customers: research end-markets — academic core labs, biotech, cancer research, agricultural genomics. Named users of Element technology include the Broad Institute and Google. Ecosystem partner SOPHiA GENETICS (AI analytics layered on Element sequencing). customers.csv is empty on disk → n/a — private, not disclosed for revenue concentration by named account.

Contract structure: instrument sale + recurring consumables. At JPM, Element introduced a throughput-based pricing model on consumables — a subscription-flavored twist that smooths the blades revenue and lowers the effective entry cost. Kit economics: an AVITI kit is ~$1,680 generating ~800M reads (2×150) — pitched as ~3× cheaper than a NextSeq kit.

One-line: Element is the best-funded, most-credible short-read benchtop challenger to Illumina, now extending from research sequencing into multiomics (AVITI24) and clinical diagnostics (AVITI Dx) — a platform-expansion story, not a single-product story.

Lens 2 · Supply Chain

Map: upstream inputs → Element → end customer.

Upstream (inputs Element depends on):

• Semiconductors / CMOS imaging sensors + optics — a sequencing instrument is fundamentally an imaging-and-fluidics machine. This is precisely where the Samsung relationship matters: Samsung Electronics is now Element's largest shareholder, and the strategic read is semiconductor/imaging supply + manufacturing scale, not just cash (see Lens 5/9).
• Flow cells — Element's proprietary flow-cell + surface chemistry (its "Cloudbreak"/"Trinity" chemistries). This is the exact locus of the Illumina patent litigation (Lens 10) — Illumina asserts flow-cell/imaging/fluid-storage patents against Element.
• Enzymes / polymerases / nucleotide reagents — the founders' domain (He led protein reagents at Illumina; Kellinger is a polymerase-engineering specialist). Reagent IP is a genuine in-house strength, reducing single-source enzyme risk relative to peers.
• Contract manufacturing (CDMO/CMO) for instruments and consumables — not publicly detailed; n/a — private, not disclosed. Samsung's manufacturing muscle is the plausible scale partner.

Element (the node): integrates chemistry + optics + fluidics + software (Cloudbreak, Trinity kits) into AVITI / AVITI24 / VITARI / AVITI Dx.

Downstream (Element → customer):

• Direct sales to core labs / biotech / cancer + ag research globally; >450 systems placed worldwide by end-2025.
• Certified Service Providers (OMAPiX, Cornell) as a channel for AVITI24 multiomics workflows.
• Software/analytics partners (SOPHiA GENETICS) as an ecosystem multiplier.

Chokepoints / single-source dependencies:

1. Flow-cell/imaging IP is both a moat and a litigation chokepoint — an adverse Illumina ruling could force redesign (Lens 10/13).
2. Samsung concentration — a single strategic that is simultaneously largest shareholder and likely a key supply/manufacturing partner is a double-edged dependency (upside: scale; downside: strategic capture / governance).
3. Instrument-grade CMOS/optics — like all sequencer makers, exposed to the semiconductor supply chain; Samsung mitigates this uniquely for Element.

Lens 3 · Competitive Advantages (moats)

What genuinely protects Element:

• Capital-cost disruption (the real edge). AVITI at ~$289K vs. NovaSeq X ~$985K–$1M is a ~3× lower entry price for competitive per-run economics ($200 genome vs. NovaSeq X 25B ~$206). For a mid-sized lab that cannot justify a $1M box, Element is the only way to get near-NovaSeq economics on a benchtop. That is a durable structural wedge in the low-to-mid-throughput tier.
• Founder/chemistry depth. Three ex-Illumina principals who literally built Illumina's reagent/chemistry stack. The reagent-and-surface chemistry is proprietary and hard to replicate — this is real process IP, not a re-badge of someone else's kit.
• Multiomics differentiation (AVITI24 / Teton). Direct on-instrument single-cell + spatial multiomics is a category Illumina's core boxes don't natively do — it reframes Element from "cheaper sequencer" to "different capability," which is a stronger competitive position than pure price.
• Strategic anchor (Samsung). A tier-1 strategic as largest shareholder confers balance-sheet durability, manufacturing scale, and semiconductor supply access that no other sequencing challenger has.

Bargaining power (who needs whom):

• Vs. customers: weak-to-moderate. Element is the challenger; switching to it is easy (low capital), but the installed base is Illumina's. Element needs the customer more than the reverse — until the consumables lock-in builds.
• Vs. Illumina (the incumbent): Illumina holds the leverage — ~80% market share, ~66% of global placements — and has been accused by Element of coercing customers (punitive consumables pricing / exclusivity pacts if they adopt AVITI). This is the crux: the moat is real on cost, but the incumbent's installed-base + coercion power is the counter-moat.

Moat verdict: a genuine cost + capability moat in the benchtop tier, undercut by an incumbent with overwhelming installed-base lock-in and (per Element's own suit) aggressive anticompetitive tactics. Not a wide moat — a contested beachhead.

Lens 4 · Segments

segments.csv is empty on disk — Element is private and does not break out audited segment revenue. Everything here is /, unaudited.

Element does not report product/geography segments. The functional decomposition of the business:

• Instruments (razor): AVITI, AVITI24, and (H2 2026) VITARI — lumpy capital sales; >450 systems placed cumulatively by end-2025, installed base +60% YoY in 2025. Install base grew from ~40 units to >190 in the prior year window (to Sept 2025), then to >450 by year-end — an inflection in placements.
• Consumables (blades): kit shipments more than doubled YoY in 2025 — the leading indicator that the razor-blade flywheel is turning. As the installed base compounds, consumables should become the dominant, higher-margin, recurring line.
• Multiomics (AVITI24 / Teton): early, service-provider-led; a growth optionality bucket, not yet material.
• Clinical (AVITI Dx): pre-revenue; launches late 2026.
• Geography: "worldwide" placements; no split disclosed → n/a — private, not disclosed.

Trend + cause: the mix is shifting from instrument-led to consumables-led (kits doubling faster than the install base grows), which is exactly the trajectory a healthy tools company wants — recurring revenue building underneath the lumpy hardware. But total revenue ($85M FY25) missed the $100M guide (see Lens 5) — the flywheel is turning slower than management promised.

---

Phase B — Measure performance (reframed: product milestones + traction, per +clinical overlay)

Lens 5 · Latest Result → Traction & Funding (no earnings print exists)

There is no quarterly earnings result — Element is private. The equivalent "print" is annual revenue traction + the funding trajectory.

Revenue traction (unaudited, management-disclosed):

• FY2025 revenue ≈ $85M, up ~40% YoY from ~$60M in FY2024.
• Critical miss: management had guided ~$100M for FY2025 at the prior year's JPM — the actual $85M is a ~15% shortfall to its own target. This is the single most important negative data point in the dossier: the growth story is real (+40%) but management over-promised and under-delivered on its most recent public number.
• Installed base +60% YoY to >450 systems; consumables kit shipments >2× YoY — the underlying flywheel is intact even though the revenue print missed.

Funding trajectory (the private "balance sheet"):

• Series C: ~$276M.
• Series D: >$277M, July 2024, led by Wellington Management; participants Samsung, Fidelity, Foresite Capital, T. Rowe Price, Venrock — brought cumulative raise to >$680M.
• Series E: June 2025, upsized, including $175M from Samsung + undisclosed others; Samsung becomes largest shareholder; total round size and valuation not disclosed.
• Cumulative raised: >$855M.
• Valuation: ~$1B reported — but the Series E round size/valuation were not publicly disclosed, so treat ~$1B as a soft, third-party estimate, not a confirmed post-money.

Burn / runway: n/a — private, not disclosed. Inference: raising a large Series E in mid-2025 after a $277M Series D in mid-2024 signals the business is not yet self-funding — instrument-tools companies are capital-intensive to scale, and back-to-back mega-rounds 11 months apart is a burn tell. Runway is a function of that undisclosed E; the Samsung anchor materially de-risks it.

Balance-sheet flags: the only hard flag is the revenue miss (execution/guidance credibility) and the implied ongoing burn (needing Series E so soon after D).

Lens 6 · Founder / management signalling (no earnings calls)

No earnings calls exist. The equivalent is founder communication + roadmap cadence (per +private overlay Lens 6):

• Molly He is an active, high-visibility communicator — CNBC Changemaker (2024), Forbes 50-over-50, podcast circuit (Mendelspod, Inside Precision Medicine, The Genomics Podcast). Messaging is consistent: "democratize sequencing / core chemistry capable of far more than the $200 genome."
• Roadmap cadence is aggressive and delivered-on (mostly): AVITI (2022) → AVITI24 (multiomics) → VITARI ($100 genome, Feb 2026) → AVITI Dx (clinical, late 2026). The annual "Beyond" event is now the product-cadence anchor (Feb 2026 delivered VITARI).
• Tone shift to watch: the pivot in language from "cheaper sequencing" (AVITI) to "ecosystem of genomic, multiomic, and clinical research solutions" (Series E framing, 2026) — a deliberate platform re-positioning, likely partly to justify valuation beyond a commoditizing sequencer.
• The credibility dent: the $100M → $85M miss sits against otherwise strong delivery. Founders who hit product timelines but miss revenue guides are a recognizable pattern — great engineers, optimistic forecasters.

Lens 7 · Cap table & mechanism/peer comps

Cap table & syndicate quality (+private overlay):

• Crossover funds present = IPO-proximity tell: Fidelity, T. Rowe Price, Wellington are all in. These are the exact late-stage crossover names that typically precede an S-1 — a genuine IPO-readiness signal (see Lens 11).
• Strategics: Samsung ($175M, largest shareholder), plus Foresite, Venrock, Morgan Stanley. A strategic-as-largest-holder is unusual and cuts both ways (Lens 3/9/13).
• Secondary marks / mutual-fund markups: n/a — not disclosed (would require Fidelity/T. Rowe holdings-report cross-reference; not available web-only here).

Peer comps (sequencing-instruments cohort — by platform, not P/E, since Element has no public multiple):

Comp read: the market has three short-read cost-disruptors (Element, Ultima, historically MGI) circling Illumina's franchise, while PacBio's exit from short-read (IP sold to Illumina, Jan 2026) actually consolidates the short-read fight down to Illumina vs. Element vs. Ultima. Element sits in the middle: cheaper capital than Illumina, less aggressive on absolute cost-per-genome than Ultima.

Lens 8 · Catalysts / events that move the story

For a private company the "stock-price" equivalent is valuation-and-narrative-moving events:

• Jul 2024 — Series D $277M (cumulative >$680M): validated the challenger thesis pre-AVITI24.
• 2025 — AVITI24 availability + Teton CSP program: repositioned Element into multiomics.
• Jun 2025 — Series E / Samsung $175M, Samsung largest shareholder: the strategic-anchor event.
• Feb 2026 — VITARI launch ($100 genome, $689K) at Beyond: the cost-competitive answer to Ultima.
• 2026 — ISO 13485 + AVITI Dx CE-IVD path: the clinical-market entry catalyst.
• Ongoing — Illumina litigation (both directions): the single biggest binary swing factor (Lens 10/13).

Pattern: Element's narrative moves on product launches and strategic capital, not on financial results (there are none public). The market (private investors) is buying roadmap execution + Samsung and discounting the revenue miss.

---

Phase C — Judge people & books

Lens 9 · Management

• Track record (quantified). Molly He (CEO/co-founder): ~8 years at Illumina as Senior Director of Protein Engineering/Scientific Research, owning Illumina's global protein-reagent innovation; won Illumina's Innovation Award twice (highest internal award, for revenue-impactful innovations); prior Head of Protein Sciences at PacBio; PhD protein biophysics UCLA. Delivered the $200 genome (2023) and the $100 genome (VITARI, 2026) — she has repeatedly shipped the cost milestones she promised. Michael Previte (CTO): physical-chemistry PhD, ex-Life Technologies + Illumina, single-molecule/imaging depth. Matthew Kellinger: polymerase/enzyme kinetics, ex-Illumina staff scientist. This is arguably the strongest founding-chemistry team of any Illumina challenger — they built the incumbent's stack.
• Tenure & skin in the game. All three founders operational since 2017; He has been CEO since inception. Founder equity is meaningful but now diluted by five rounds (C/D/E + earlier) and, critically, Samsung is the largest shareholder — founder control is no longer dominant. Exact insider ownership: n/a — private, not disclosed.
• Capital-allocation history. Raised >$855M and deployed it into (a) commercializing AVITI, (b) building AVITI24 multiomics, (c) VITARI high-throughput, (d) AVITI Dx clinical + ISO 13485 QMS. This is coherent, roadmap-disciplined allocation — each raise funded a named next platform. The knock: capital intensity is high and the business still isn't self-funding (Series E 11 months after D).
• Red flags. (1) The $100M → $85M revenue miss — a guidance-credibility ding. (2) Samsung-as-largest-shareholder — a governance concentration where a strategic supplier/partner controls the biggest stake (potential conflict on M&A, exit, supply terms). (3) Aggressive, litigation-heavy posture toward Illumina (offensive and defensive suits) — justified competitively, but it means legal risk is structural. No evidence of self-dealing, excessive comp, or promotional accounting surfaced (private → limited visibility).
• Founder vs. professional manager. Clearly founder-scientist-led — the archetype that fits a deep-tech tools company at this stage (technical credibility drives customer trust and roadmap). The risk of that archetype: commercial/forecasting discipline (the revenue miss is the tell). Element has been adding senior commercial/corporate-development executives to shore up exactly that gap.

Lens 10 · Forensic Red Flags + Regulatory

Accounting red flags: Element is private and unaudited-in-public — there is no income statement, balance sheet, or cash-flow statement to forensically examine. Standard flags (rev-rec, receivables vs. revenue, SBC, goodwill) cannot be assessed → n/a — private, no audited financials disclosed. The only quasi-forensic signal available is the guidance miss ($100M→$85M), which points to optimistic forecasting rather than any accounting impropriety. All private-company figures in this dossier are unaudited per public sources.

Regulatory findings (read from regulatory/regulatory-findings.md, generated 2026-07-01):

• SEC (EDGAR EFTS — LR + AAER): 0 findings. Element has no CIK and is not an SEC registrant, so no SEC enforcement search is possible.
• Non-SEC enforcement (web search): search on "Element Biosciences" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement surfaced no government enforcement actions, fines, or consent decrees against Element. The only "FDA/regulatory" involvement is proactive and favorable — Element pursuing ISO 13485 + CE-IVD for AVITI Dx (a market-entry credential, not an enforcement matter).
• Litigation (the material item) — Item-3-equivalent, from public disclosure: Element and Illumina are in active, dual-direction patent + antitrust litigation (Delaware / N.D. Cal. / Munich Regional Court I):
• Illumina → Element: infringement of five patents covering flow cell, imaging, and fluid-storage instrument design; seeks damages + injunction.
• Element → Illumina: patent-infringement countersuits (4 US patents in Delaware + patents asserted in Munich), plus antitrust / anticompetitive-conduct, defamation and trade-libel claims — alleging Illumina threatened customers with punitive consumables/service pricing and sought exclusivity pacts to block AVITI adoption.
• Status (2026): still early — motion practice ongoing; a motion to dismiss deemed moot in light of Element's First Amended Complaint as of Jan 2026; no ruling, verdict, or settlement. No ITC proceeding identified.
• Summary: No SEC/AAER, FTC, DOJ, or FDA enforcement — verified via SEC EDGAR EFTS (LR, AAER), web search, and public litigation dockets as of 2026-07-01. The one material legal exposure is the Illumina patent litigation — an unresolved binary that could (bear) force a flow-cell redesign / injunction / damages, or (bull) validate Element's IP and expose Illumina to antitrust liability. Unaudited per public sources.

---

Phase D — Project & stress-test

Lens 11 · IPO-readiness & path-to-tradeable (+private overlay Lens 11)

No private-watch.json entry exists for element-biosciences → this lens is grounded on web-sourced stage/funding data, not the IPO-readiness ledger. (I am not writing back to private-watch.json — this is an unattended breadth run inside a wave with edit boundaries; flagged here as an open item for Connor to add the entry.)

IPO-readiness assessment:

• Stage: Late-stage, revenue-generating (~$85M FY25), Series E-funded, crossover investors already on the cap table (Fidelity, T. Rowe, Wellington) — the pre-IPO configuration.
• Milestones that unlock an S-1:

1. VITARI ships (H2 2026) and demonstrates the $100-genome at scale — proves the high-throughput SKU can compete with NovaSeq X / Ultima on the metric public markets will underwrite.
2. AVITI Dx clears CE-IVD (late 2026+) — opens the clinical TAM, the multiple-expanding narrative vs. a research-only tools story.
3. Consumables mix crosses ~50% of revenue — the recurring-revenue quality public markets pay up for (already trending: kits >2× YoY).
4. Illumina litigation resolves or de-risks — an IPO into an unresolved injunction risk is hard; a settlement or favorable ruling is a gating item.
5. Revenue re-acceleration past the $100M level it already missed — restore the guidance credibility.

• Estimated window: not before 2027, more likely 2027–2028 — contingent on VITARI shipping cleanly, AVITI Dx traction, litigation clearing, and (heavily) the genomics-IPO tape reopening (the sector's IPO window has been shut/hostile; the biotech-tools comp set has de-rated). Samsung as largest shareholder also raises an alternative-exit possibility: a strategic acquisition by Samsung (vertical integration into life-science instruments) could pre-empt an IPO entirely.

"Forecast" note: per skill, in the --watchlist loop no forecast.ts create is logged (only log a Brier forecast on genuine conviction). No EPS line exists for a private company; the trackable binary would be "Element files an S-1 / trades by YYYY" or "VITARI ships in H2 2026" — not logged in this breadth pass.

Lens 12 · Bull vs Bear

Bull case. Element is the only credible short-read benchtop challenger to a resented ~80%-share monopolist, with (1) a structural capital-cost wedge (AVITI $289K vs. NovaSeq X ~$1M) that opens the mid-market Illumina can't defend without cannibalizing its own high-end boxes; (2) a tier-1 strategic anchor (Samsung, largest shareholder) supplying capital, semiconductor/imaging supply, and manufacturing scale; (3) a capability differentiator (AVITI24 multiomics / Teton) that reframes it from "cheaper sequencer" to "new modality"; (4) a clinical option (AVITI Dx / CE-IVD) that expands TAM from research into diagnostics; (5) the strongest founding-chemistry team of any challenger, delivering cost milestones on cadence ($200→$100 genome); and (6) crossover investors + Samsung creating both an IPO path and a strategic-acquisition floor. If Element wins even a modest share of the benchtop consumables stream, the razor-blade annuity compounds into a multi-hundred-million recurring-revenue franchise.

Bear case (permanent-impairment risks). (1) The cost floor is Ultima's, not Element's — Ultima's $80 genome (UG200) undercuts VITARI's $100, and in a commoditizing metric the lowest cost curve wins the high-throughput accounts; Element risks being squeezed between Illumina's installed-base lock-in above and Ultima's cost curve below. (2) Illumina's counter-moat is coercive and structural — 80% share + (per Element's own antitrust suit) punitive consumables pricing and exclusivity pacts that make switching genuinely costly for customers; a monopolist defending its consumables annuity is a brutal opponent. (3) The litigation is an unresolved injunction risk on Element's core flow-cell IP — an adverse ruling could force redesign or block sales. (4) Execution/guidance credibility — the $100M→$85M miss says the commercial ramp is harder than management models. (5) Capital intensity — back-to-back mega-rounds mean continued dilution and dependence on a supportive private market / Samsung; a shut IPO window prolongs the burn.

Pre-mortem (18 months out, thesis broke): VITARI shipped late or with yield/quality issues; Ultima's $80 genome took the high-throughput accounts while Illumina's NovaSeq X 25B ($2/Gb) held the top and its coercion held the installed base; Element's revenue stalled near ~$100–120M instead of re-accelerating; an adverse (or expensively-settled) Illumina ruling hit the flow-cell chemistry; the IPO window stayed shut and the next round came at a flat-to-down valuation, resetting the ~$1B mark. Samsung, now largest shareholder, moved to buy the whole company cheaply.

Are multiples too high? The ~$1B valuation on ~$85M revenue (~11–12× trailing revenue, soft) is rich for a hardware-heavy tools company that just missed its own guide, in a genomics-tools comp set that has de-rated hard. Justified only if you underwrite the consumables annuity + clinical optionality + Samsung strategic value. Priced for execution it hasn't yet delivered.

Contrarian view (what the market refuses to see): The consensus frames this as "plucky challenger vs. Illumina." The more important, under-priced fact is Samsung. A semiconductor giant taking the largest stake in a benchtop sequencer is not a passive financial bet — it is a vertical-integration option on the life-science-instruments supply chain (imaging sensors, fluidics, manufacturing). The real Element trade may not be "does it out-compete Illumina" but "does Samsung eventually buy it" — which caps the downside and reframes the IPO question entirely.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Where revenue is concentrated / what breaks it: research end-markets (academic + biotech) are NIH/grant-funding-sensitive and budget-cyclical — a life-science-tools funding downturn (as the sector has seen) hits instrument capex first. Element's revenue is exactly the discretionary capital-equipment line that gets deferred. Named-account concentration is undisclosed but the customer base is smaller than Illumina's, so any large-lab churn back to Illumina (under coercive pricing) is outsized.
• Why the moat is weaker than bulls think: the "cost moat" is a moving target Element doesn't own the floor of. Ultima ($80) is below it; Illumina's NovaSeq X 25B is pushing to $2/Gb at the top. Cost leadership in a commodity metric is the weakest kind of moat — someone always goes lower. The durable asset is the installed-base consumables lock-in, and Illumina owns that, not Element.
• Most dangerous competitor bulls underestimate: not Illumina — Ultima Genomics. Ultima is the one actually beating Element on the cost metric Element markets on, and it's equally well-funded and private. In the high-throughput tier VITARI targets, Ultima is the sharper knife.
• Worst capital-allocation / governance: Samsung-as-largest-shareholder is the short's favorite angle — a strategic supplier controlling the biggest equity stake creates conflicts on supply pricing, M&A, and exit timing, and could trap minority/founder holders in a low-ball strategic acquisition. Plus five rounds of dilution and a business that still can't self-fund.
• Assumptions that must hold for ~$1B: VITARI ships on time and at quality; consumables annuity compounds; AVITI Dx opens clinical without a regulatory stumble; Illumina litigation doesn't injunct the flow cell; the IPO/exit window reopens; revenue re-accelerates past $100M. That's six sequential things going right — a fragile stack.
• If growth disappoints 20–30%: at ~$85M actual vs. a $100M miss, a further 20–30% shortfall on the next target (say ~$110M instead of a hoped ~$150M) would break the ~11–12× revenue mark and likely force a down round, resetting the ~$1B valuation and the IPO timeline.
• Single permanently-impairing scenario (most plausible): an adverse Illumina patent ruling / injunction on the flow-cell chemistry that forces a redesign or halts AVITI sales while Ultima takes the cost-sensitive accounts — Element loses its window during the redesign. Plausibility: moderate — patent cases are unpredictable and Illumina has a mixed record (it paid $325M to settle with BGI affiliates ), but the risk is real and unquantifiable, which is itself the problem for an IPO.

Lens 14 · Management Questions (ordered by information value)

1. VITARI ships H2 2026 — what is the current committed backlog/pre-order book in units and dollars, and what yield/quality data supports the $100-genome claim at production scale? (The whole high-throughput thesis rides on this.)
2. Ultima is at an $80 genome with the UG200 — on which specific accounts are you winning vs. Ultima and Illumina today, and what is your defensible cost floor?
3. What was the root cause of the FY25 $85M-vs-$100M-guide miss, and what has structurally changed in the commercial model so it doesn't recur?
4. Samsung is now your largest shareholder — what are the exact governance rights, board seats, supply-agreement terms, and any exclusivity or right-of-first-refusal on an acquisition?
5. What is your current cash runway (months) at present burn, and does it reach VITARI shipment + AVITI Dx CE-IVD without another raise?
6. On the Illumina litigation — what is your realistic range of outcomes on the flow-cell patents, and what is your redesign contingency if an injunction lands?
7. What share of revenue is now recurring consumables vs. instruments, and when do you cross 50%?
8. Illumina allegedly coerces customers with punitive consumables pricing — quantify how much this has actually cost you in lost placements, and how the antitrust suit changes that.
9. What is the AVITI Dx clinical commercial plan post-CE-IVD — which assays, which countries, what reimbursement path, and US FDA timeline?
10. Is your medium-term plan an IPO or a strategic exit, and what specifically has to be true for you to file an S-1?
11. What is AVITI24 / Teton multiomics contributing to revenue today, and is it a real growth line or a differentiation halo?
12. What is your gross margin on instruments vs. consumables, and where does blended gross margin go at scale?
13. Where is your manufacturing capacity for VITARI, and how much of it depends on Samsung?
14. PacBio just sold its short-read IP to Illumina — does that consolidation change your IP-freedom-to-operate or competitive positioning?
15. What is your customer concentration — what % of revenue is your top 10 accounts, and how much is grant-funding-dependent?

---